Final answer:
The primary and secondary endpoints for the EMPA-Preserved Trial were cardiovascular death or hospitalization for heart failure and kidney disease progression, all-cause mortality, hospitalization for heart failure, and symptoms in patients with HFpEF.
Step-by-step explanation:
The primary and secondary endpoints for the EMPA-Preserved Trial were:
Primary Endpoint: The effect of empagliflozin compared to placebo on cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction (HFpEF).
Secondary Endpoints: The effect of empagliflozin compared to placebo on kidney disease progression, all-cause mortality, hospitalization for heart failure, and symptoms in patients with HFpEF.